FDA officials stress natural history studies in supporting rare disease drug development
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy